Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Mereo Biopharma Group Plc (0A9G) Share Price & Analysis

1 Followers

0A9G Stock Chart & Stats

$0.30-$0.01(-1.96%)
At close: 4:30 PM GMT
$0.25$0.3$0.35$0.4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.29 - $0.31
52-Week Range
$0.22 - $2.36
Previous Close
$0.31
Volume
N/A
Average Volume (3M)
31.76K
Market Cap
$48.96M
Enterprise Value
$39.16M
Total Cash (Recent Filing)
$26.10M
Total Debt (Recent Filing)
$577.00K
Price to Earnings (P/E)
―
Beta
0.60
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
-0.02
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces near-term solvency pressure and leaves the company less exposed to interest costs or refinancing demands. This provides some financial flexibility while Mereo advances its clinical pipeline and seeks partnership-related funding.

Alvelestat Partnership

The Sentynl agreement validates a capital-light partnership model and creates multiple potential funding and value inflection points. Upfront payments, development milestones, and royalties could extend runway and reduce the burden of independently commercializing alvelestat.

Pipeline Advancement

Progress toward a Phase 3 program gives alvelestat a clearer development path and could strengthen Mereo’s rare-disease platform. Continued regulatory engagement and partner collaboration may improve the pipeline’s ability to generate future licensing or royalty value.

Bears Say

Persistent Cash Burn

Mereo remains dependent on external funding, partnerships, or future milestone receipts because operations are not self-financing. Continued negative cash flow can shorten liquidity duration and constrain investment in clinical programs if expected inflows are delayed.

Weak Revenue And Profitability

Current revenue is far below the cost base, leaving the company structurally loss-making despite some improvement from 2025. Until partnering income becomes more consistent or a product reaches commercialization, earnings visibility and operating leverage remain weak.

Nasdaq Compliance Risk

The extended bid-price deficiency creates an ongoing listing and financing overhang through early 2027. Failure to regain compliance could reduce market access and visibility, complicate capital raising, and add pressure to management while clinical execution remains critical.

Mereo Biopharma Group Plc News

0A9G FAQ

What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest share price was $0.22 and its highest was $2.36 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $48.96M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 137 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Nov 09, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.016 by $0.006.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.02.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,700,640 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.016. Following the earnings report the stock price went up 7.857%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Hedge funds hold Mereo Biopharma Group Plc shares: the largest hedge-fund position in Mereo Biopharma Group Plc is 708,123,449 shares, and hedge funds decreased their holdings by 517.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology